RXST241220P62500
- 17.64
- 0.000.00%
RxSight Newsroom
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $70
BofA Securities Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $60
Stifel Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $65
Wells Fargo Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $56
BofA Securities Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $60
Needham Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $66
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Artivion (AORT) and RxSight (RXST)
RxSight's Strong Growth and Market Positioning Earns Buy Rating From Analyst
RxSight Analyst Ratings
Jefferies Initiates RxSight(RXST.US) With Buy Rating, Announces Target Price $72
BTIG Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $59
Needham Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $66
RxSight's Growth Trajectory: A Buy Recommendation on Strong Revenue Prospects and International Expansion
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $70
RxSight Price Target Raised to $66.00/Share From $54.00 by Needham
RxSight Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and RxSight (RXST)
Needham Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $66
Oppenheimer Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $65
A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $54 to $70